Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort
Top Cited Papers
Open Access
- 18 November 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 114 (3) , 448-454
- https://doi.org/10.1002/ijc.20710
Abstract
Most epidemiological studies have shown an increase in breast cancer risk related to hormone replacement therapy (HRT) use. A recent large cohort study showed effects of similar magnitude for different types of progestogens and for different routes of administration of estrogens evaluated. Further investigation of these issues is of importance. We assessed the risk of breast cancer associated with HRT use in 54,548 postmenopausal women who had never taken any HRT 1 year before entering the E3N‐EPIC cohort study (mean age at inclusion: 52.8 years); 948 primary invasive breast cancers were diagnosed during follow‐up (mean duration: 5.8 years). Data were analyzed using multivariate Cox proportional hazards models. In this cohort where the mean duration of HRT use was 2.8 years, an increased risk in HRT users compared to nonusers was found (relative risk (RR) 1.2 [95% confidence interval 1.1–1.4]). The RR was 1.1 [0.8–1.6] for estrogens used alone and 1.3 [1.1–1.5] when used in combination with oral progestogens. The risk was significantly greater (p <0.001) with HRT containing synthetic progestins than with HRT containing micronized progesterone, the RRs being 1.4 [1.2–1.7] and 0.9 [0.7–1.2], respectively. When combined with synthetic progestins, both oral and transdermal/percutaneous estrogens use were associated with a significantly increased risk; for transdermal/percutaneous estrogens, this was the case even when exposure was less than 2 years. Our results suggest that, when combined with synthetic progestins, even short‐term use of estrogens may increase breast cancer risk. Micronized progesterone may be preferred to synthetic progestins in short‐term HRT. This finding needs further investigation.Keywords
This publication has 40 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in EuropeInternational Journal of Cancer, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Hormone replacement therapy regimens and breast cancer riskObstetrics & Gynecology, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Serum insulin-like growth factor-I and breast cancerInternational Journal of Cancer, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center studyJournal of Clinical Endocrinology & Metabolism, 1996
- The role of oestrogens and progestagens in the epidemiology and prevention of breast cancerEuropean Journal of Cancer and Clinical Oncology, 1988